CBD study for baby seizures halted early

NCT ID NCT04485104

Terminated Symptom relief Sponsor: Jazz Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a cannabidiol (CBD) oral solution in children under 2 years old with tuberous sclerosis complex, Dravet syndrome, or Lennox-Gastaut syndrome who had uncontrolled seizures. The goal was to see if CBD is safe and can reduce seizures. However, the study was terminated early after enrolling only 3 participants, so we have very little information about how well it works or its risks in this young age group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cannabidiol (CBD) oral solution
What this could lead to: If successful, this could provide a treatment option to reduce seizures in very young children with these rare conditions.
What could go wrong: The study was terminated early with only 3 participants, so results are very limited. It is unclear if CBD is safe or effective in this age group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEIZURE IN PARTICIPANTS WITH DRAVET SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dravet syndrome Epilepsies, Myoclonic epilepsy Lennox-Gastaut syndrome Spasms, Infantile tuberous sclerosis tuberous sclerosis 1 tuberous sclerosis 2 visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEIZURE IN PARTICIPANTS WITH DRAVET SYNDROME SEIZURE IN PARTICIPANTS WITH LENNOX-GASTAUT SYNDROME SEIZURE IN PARTICIPANTS WITH TUBEROUS SCLEROSIS COMPLEX

Contacts and locations

Locations

Clinical Trial Site

Little Rock, Arkansas, 72202, United States
Clinical Trial Site

Los Angeles, California, 90095, United States
Clinical Trial Site

Chicago, Illinois, 60611, United States
Clinical Trial Site

Boston, Massachusetts, 02114, United States
Clinical Trial Site

Cincinnati, Ohio, 45229, United States
Clinical Trial Site

Houston, Texas, 77030, United States
Clinical Trial Site

Florence, 50139, Italy
Clinical Trial Site

Genova, 16147, Italy
Clinical Trial Site

Rome, 00165, Italy
Clinical Trial Site

Barcelona, 08950, Spain
Clinical Trial Site

Madrid, 28034, Spain